<p>巴克萊在週二向客户和投資者發佈的研究報告中開始覆蓋 ANI 製藥（NASDAQ:ANIP - 獲取免費報告）的股票，Benzinga 報道。該公司對這家專業製藥公司的股票設定了 “增持” 評級和 100.00 美元的目標價。巴克萊的目標價意味着該股票相較於之前的收盤價有 20.90% 的潛在上漲空間。</p>
<p>其他幾位股票研究分析師也對該股票發佈了報告。HC Wainwright 將 ANI 製藥的目標價從 93.00 美元上調至 121.00 美元，並在 9 月 17 日的報告中給予該股票 “買入” 評級。Truist Financial 在 10 月 9 日的報告中將 ANI 製藥的目標價從 77.00 美元上調至 90.00 美元，並給予該公司 “持有” 評級。Weiss Ratings 在 12 月 1 日的研究報告中重新發布了 ANI 製藥的 “買入（b-）” 評級。華爾街 Zen 在 8 月 16 日的研究報告中將 ANI 製藥的評級從 “買入” 上調至 “強力買入”。最後，Zacks Research 在 8 月 21 日的研究報告中將 ANI 製藥的評級從 “持有” 上調至 “強力買入”。兩位投資分析師給予該股票 “強力買入” 評級，八位給予 “買入” 評級，一位給予 “持有” 評級。根據 MarketBeat 的數據，該公司的共識評級為 “買入”，共識目標價為 99.38 美元。</p>
<p>獲取 <strong>ANI 製藥</strong> 的提醒：</p>
<p><strong>查看我們對 ANIP 的最新分析</strong></p>
<h2>ANI 製藥股票表現</h2>
<p>在週二的午盤交易中，NASDAQ:ANIP 上漲 1.37 美元，達到 82.71 美元。該公司交易了 45,984 股，相比其 375,563 的平均交易量。該公司的速動比率為 2.04，流動比率為 2.58，債務與股本比率為 1.20。該股票的 50 日移動平均價格為 88.29 美元，200 日移動平均價格為 80.19 美元。該公司的市值為 18.6 億美元，市盈率為 50.74，貝塔值為 0.48。ANI 製藥的年低為 52.50 美元，年高為 99.50 美元。</p>
<p>ANI 製藥（NASDAQ:ANIP - 獲取免費報告）最近於 11 月 7 日發佈了其財報。這家專業製藥公司報告本季度每股收益為 2.04 美元，超出分析師共識預期的 1.74 美元，超出幅度為 0.30 美元。該公司本季度的收入為 2.2781 億美元，而分析師預期為 2.1192 億美元。ANI 製藥的淨利潤率為 4.91%，股本回報率為 26.73%。ANI 製藥本季度的收入同比增長 53.6%。在去年同期，該公司每股收益為 1.34 美元。ANI 製藥已將其 2025 財年的指導目標設定為每股收益 7.370-7.640 美元。研究分析師預計 ANI 製藥在當前財年將發佈 3.86 美元的每股收益。</p>
<h2>內部活動</h2>
<p>在其他消息中，SVP Chad Gassert 於 11 月 12 日星期三出售了 14,642 股公司的股票。該股票以 89.07 美元的平均價格出售，總交易額為 1,304,162.94 美元。出售後，這位高級副總裁直接持有 158,584 股公司的股票，價值 14,125,076.88 美元。這筆交易代表其持股減少了 8.45%。該交易已在證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上找到。此外，SVP Krista Davis 於 9 月 19 日星期五出售了 1,000 股公司的股票。該股票以 98.04 美元的平均價格出售，總價值為 98,040.00 美元。交易後，這位高級副總裁直接持有 60,186 股公司的股票，價值約為 5,900,635.44 美元。這筆交易使其持股減少了 1.63%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士出售了價值 2,271,691 美元的 25,579 股公司股票。內部人士持有公司股票的 12.70%。</p>
<h2>機構資金流入和流出</h2>
<p>最近幾家對沖基金已增持或減持了在該公司的股份。Advisors Asset Management Inc.在第一季度購買了價值約 28,000 美元的 ANI 製藥新股份。Hantz Financial Services Inc.在第三季度將其在 ANI 製藥的股份增加了 202.6%。Hantz Financial Services Inc.現在擁有 354 股這家專業製藥公司的股票，價值 32,000 美元，此前在該期間內增持了 237 股。Caitong International Asset Management Co. Ltd 在第二季度將其在 ANI 製藥的股份增加了 4,636.4%。Caitong International Asset Management Co. Ltd 現在擁有 521 股這家專業製藥公司的股票，價值 34,000 美元，此前在該期間內增持了 510 股。Newbridge Financial Services Group Inc.在第二季度將其在 ANI 製藥的股份增加了 200.0%。Newbridge Financial Services Group Inc.現在擁有 600 股這家專業製藥公司的股票，價值 39,000 美元，此前在上個季度增持了 400 股。最後，懷俄明州在第二季度購買了價值約 50,000 美元的 ANI 製藥新股份。76.05% 的股票由機構投資者和對沖基金持有。</p>
<h2>ANI 製藥公司簡介</h2>
<p>（獲取免費報告）</p>
<p>ANI 製藥公司是一家生物製藥公司，在美國和加拿大開發、製造和銷售品牌和仿製處方藥。該公司生產口服固體劑型產品；半固體、液體和外用劑型；受控物質；以及強效產品，並進行藥品的合同開發和製造。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，而不是 ANI Pharmaceuticals</li>
<li>適合波動時期的三隻沃倫·巴菲特必買股票</li>
<li>到 2026 年油價可能跌至 55 美元——這對該能源 ETF 來説是壞消息</li>
<li>什麼是稀釋每股收益（Diluted EPS）？</li>
<li>在 2026 年第一季度之前購買的五隻高空頭頭寸股票</li>
<li>十月份值得考慮購買的三隻股票</li>
<li>為什麼這三隻汽車和工業芯片股票剛剛飆升</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 ANI Pharmaceuticals 嗎？</h2>
<p>在你考慮 ANI Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 ANI Pharmaceuticals 並不在名單上。</p>
<p>雖然 ANI Pharmaceuticals 目前在分析師中有買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ANI制藥

<p>巴克萊對 ANI 製藥啓動了覆蓋，給予 “增持” 評級，目標價為 100 美元，暗示潛在上漲空間為 20.90%。其他分析師也發佈了積極評級，普遍給予 “買入” 評級，目標價為 99.38 美元。ANI 製藥報告了強勁的收益，年收入同比增長 53.6%。內部交易活動包括高級副總裁的大量股票出售。機構投資者已調整在該公司的持股比例</p>

<p>Barclays assumed coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm set an &#34;overweight&#34; rating and a $100.00 price target on the specialty pharmaceutical company's stock. Barclays's price target would indicate a potential upside of 20.90% from the stock's previous close.</p>
<div class="lb-trans"><p>巴克萊在週二向客户和投資者發佈的研究報告中開始覆蓋 ANI 製藥（NASDAQ:ANIP - 獲取免費報告）的股票，Benzinga 報道。該公司對這家專業製藥公司的股票設定了 “增持” 評級和 100.00 美元的目標價。巴克萊的目標價意味着該股票相較於之前的收盤價有 20.90% 的潛在上漲空間。</p>
</div><p>Several other equities research analysts have also issued reports on the stock. HC Wainwright raised their target price on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, September 17th. Truist Financial boosted their price target on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a &#34;hold&#34; rating in a report on Thursday, October 9th. Weiss Ratings reissued a &#34;buy (b-)&#34; rating on shares of ANI Pharmaceuticals in a research note on Monday, December 1st. Wall Street Zen raised ANI Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, August 16th. Finally, Zacks Research raised ANI Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $99.38.</p>
<div class="lb-trans"><p>其他幾位股票研究分析師也對該股票發佈了報告。HC Wainwright 將 ANI 製藥的目標價從 93.00 美元上調至 121.00 美元，並在 9 月 17 日的報告中給予該股票 “買入” 評級。Truist Financial 在 10 月 9 日的報告中將 ANI 製藥的目標價從 77.00 美元上調至 90.00 美元，並給予該公司 “持有” 評級。Weiss Ratings 在 12 月 1 日的研究報告中重新發布了 ANI 製藥的 “買入（b-）” 評級。華爾街 Zen 在 8 月 16 日的研究報告中將 ANI 製藥的評級從 “買入” 上調至 “強力買入”。最後，Zacks Research 在 8 月 21 日的研究報告中將 ANI 製藥的評級從 “持有” 上調至 “強力買入”。兩位投資分析師給予該股票 “強力買入” 評級，八位給予 “買入” 評級，一位給予 “持有” 評級。根據 MarketBeat 的數據，該公司的共識評級為 “買入”，共識目標價為 99.38 美元。</p>
</div><p>Get <strong>ANI Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>ANI 製藥</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Analysis on ANIP</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ANIP 的最新分析</strong></p>
</div><h2>ANI Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>ANI 製藥股票表現</h2>
</div><p>NASDAQ:ANIP traded up $1.37 during mid-day trading on Tuesday, hitting $82.71. 45,984 shares of the company traded hands, compared to its average volume of 375,563. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The stock's fifty day moving average price is $88.29 and its 200-day moving average price is $80.19. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of 50.74 and a beta of 0.48. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $99.50.</p>
<div class="lb-trans"><p>在週二的午盤交易中，NASDAQ:ANIP 上漲 1.37 美元，達到 82.71 美元。該公司交易了 45,984 股，相比其 375,563 的平均交易量。該公司的速動比率為 2.04，流動比率為 2.58，債務與股本比率為 1.20。該股票的 50 日移動平均價格為 88.29 美元，200 日移動平均價格為 80.19 美元。該公司的市值為 18.6 億美元，市盈率為 50.74，貝塔值為 0.48。ANI 製藥的年低為 52.50 美元，年高為 99.50 美元。</p>
</div><p>ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.74 by $0.30. The company had revenue of $227.81 million for the quarter, compared to analysts' expectations of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. ANI Pharmaceuticals's revenue for the quarter was up 53.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Research analysts anticipate that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>ANI 製藥（NASDAQ:ANIP - 獲取免費報告）最近於 11 月 7 日發佈了其財報。這家專業製藥公司報告本季度每股收益為 2.04 美元，超出分析師共識預期的 1.74 美元，超出幅度為 0.30 美元。該公司本季度的收入為 2.2781 億美元，而分析師預期為 2.1192 億美元。ANI 製藥的淨利潤率為 4.91%，股本回報率為 26.73%。ANI 製藥本季度的收入同比增長 53.6%。在去年同期，該公司每股收益為 1.34 美元。ANI 製藥已將其 2025 財年的指導目標設定為每股收益 7.370-7.640 美元。研究分析師預計 ANI 製藥在當前財年將發佈 3.86 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other news, SVP Chad Gassert sold 14,642 shares of the firm's stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $89.07, for a total transaction of $1,304,162.94. Following the sale, the senior vice president directly owned 158,584 shares in the company, valued at $14,125,076.88. This trade represents a 8.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $98.04, for a total value of $98,040.00. Following the transaction, the senior vice president directly owned 60,186 shares of the company's stock, valued at approximately $5,900,635.44. The trade was a 1.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 25,579 shares of company stock valued at $2,271,691. Insiders own 12.70% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，SVP Chad Gassert 於 11 月 12 日星期三出售了 14,642 股公司的股票。該股票以 89.07 美元的平均價格出售，總交易額為 1,304,162.94 美元。出售後，這位高級副總裁直接持有 158,584 股公司的股票，價值 14,125,076.88 美元。這筆交易代表其持股減少了 8.45%。該交易已在證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上找到。此外，SVP Krista Davis 於 9 月 19 日星期五出售了 1,000 股公司的股票。該股票以 98.04 美元的平均價格出售，總價值為 98,040.00 美元。交易後，這位高級副總裁直接持有 60,186 股公司的股票，價值約為 5,900,635.44 美元。這筆交易使其持股減少了 1.63%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士出售了價值 2,271,691 美元的 25,579 股公司股票。內部人士持有公司股票的 12.70%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several hedge funds have recently added to or reduced their stakes in the company. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals in the first quarter valued at approximately $28,000. Hantz Financial Services Inc. raised its stake in shares of ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company's stock valued at $32,000 after acquiring an additional 237 shares during the period. Caitong International Asset Management Co. Ltd boosted its position in shares of ANI Pharmaceuticals by 4,636.4% during the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company's stock worth $34,000 after buying an additional 510 shares during the period. Newbridge Financial Services Group Inc. grew its position in ANI Pharmaceuticals by 200.0% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company's stock valued at $39,000 after acquiring an additional 400 shares in the last quarter. Finally, State of Wyoming purchased a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $50,000. 76.05% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>最近幾家對沖基金已增持或減持了在該公司的股份。Advisors Asset Management Inc.在第一季度購買了價值約 28,000 美元的 ANI 製藥新股份。Hantz Financial Services Inc.在第三季度將其在 ANI 製藥的股份增加了 202.6%。Hantz Financial Services Inc.現在擁有 354 股這家專業製藥公司的股票，價值 32,000 美元，此前在該期間內增持了 237 股。Caitong International Asset Management Co. Ltd 在第二季度將其在 ANI 製藥的股份增加了 4,636.4%。Caitong International Asset Management Co. Ltd 現在擁有 521 股這家專業製藥公司的股票，價值 34,000 美元，此前在該期間內增持了 510 股。Newbridge Financial Services Group Inc.在第二季度將其在 ANI 製藥的股份增加了 200.0%。Newbridge Financial Services Group Inc.現在擁有 600 股這家專業製藥公司的股票，價值 39,000 美元，此前在上個季度增持了 400 股。最後，懷俄明州在第二季度購買了價值約 50,000 美元的 ANI 製藥新股份。76.05% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>ANI Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>ANI 製藥公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.</p>
<div class="lb-trans"><p>ANI 製藥公司是一家生物製藥公司，在美國和加拿大開發、製造和銷售品牌和仿製處方藥。該公司生產口服固體劑型產品；半固體、液體和外用劑型；受控物質；以及強效產品，並進行藥品的合同開發和製造。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than ANI Pharmaceuticals</li>
<li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li>
<li>Oil Prices May Fall to $55 by 2026—Bad News for This Energy ETF</li>
<li>What is diluted earnings per share (Diluted EPS)?</li>
<li>5 High Short-Interest Stocks to Buy Before Q1 2026</li>
<li>3 Stocks to Consider Buying in October</li>
<li>Why These 3 Automotive &amp; Industrial Chip Stocks Just Soared</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 ANI Pharmaceuticals</li>
<li>適合波動時期的三隻沃倫·巴菲特必買股票</li>
<li>到 2026 年油價可能跌至 55 美元——這對該能源 ETF 來説是壞消息</li>
<li>什麼是稀釋每股收益（Diluted EPS）？</li>
<li>在 2026 年第一季度之前購買的五隻高空頭頭寸股票</li>
<li>十月份值得考慮購買的三隻股票</li>
<li>為什麼這三隻汽車和工業芯片股票剛剛飆升</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ANIP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in ANI Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 ANI Pharmaceuticals 嗎？</h2>
</div><p>Before you consider ANI Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 ANI Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 ANI Pharmaceuticals 並不在名單上。</p>
</div><p>While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 ANI Pharmaceuticals 目前在分析師中有買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

巴克萊的分析師已開始對 ANI 製藥（NASDAQ:ANIP）進行研究覆蓋